Spotlight on

Coronavirus (COVID-19)

A Message from our Managing Partner

It seems we now move into a new stage of the pandemic, where we must all learn to live with the situation and resume our normal lives where possible. At Mewburn Ellis our offices are now open and our people are returning on a phased basis with the aim of everyone being back in at least some of the time from the end of September. To keep our people as safe as possible, we have taken the decision to maintain our offices as COVID-19 secure and the screens, one way systems, mask use and social distancing remain in place. We believe this is a sensible approach for now to maintain the health and wellbeing of our staff.

We’ve taken the last few months to think about what we want our firm to look like in light of everything we’ve all experienced during the pandemic and we’ve also consulted with our people so everyone’s voice has been heard. We’ve seen the benefits of home working for our business and our people, but we also recognise some of the challenges it brings too and what we lose by not being physically together. In light of this we have decided to create a ‘blended working’ approach where we expect everyone to be in the office 50% of the time and we have introduced more flexibility around start and finish times so our teams are able to travel during quieter times of the day and manage their professional and personal commitments in a balanced and effective way.

We know that innovation goes into overdrive in challenging times and these last 18 months have been no exception. It’s been wonderful to work with our clients on so many new and exciting projects during this time as science continues to improve our lives through the amazing shared innovation that is taking place across the world. Speaking to our clients we know you have all handled the last 18 months in different ways. Some have changed their business models and reinvented themselves and some have simply had to wait out this horrible situation but are now moving into a more positive phase. Many have also been innovating, sharing ideas and working with people they would have previously been in competition, suspending this for the greater good. This spotlight page brings you the latest commentary from our attorneys about Coronavirus (COVID-19) and how it affects IP, as well as any legal updates you need to know. We are also showcasing some of the inspirational work our clients are doing. We continue to add to this, so do check back to see new stories.  

In the meantime we hope that you and yours remain well. We're here to help if you need us. If you need IP advice or simply want to chat do pick up the phone we would love to hear from you.

Best wishes

Richard-1

Richard Clegg

Read our Coronavirus (COVID-19) Blogs

Covid autumn booster vaccine 2023: the switch to mono-valent vaccines

Covid autumn booster vaccine 2023: the switch to mono-valent vaccines

Autumn 2023 sees another round of COVID-19 booster jabs across the UK for vulnerable people.

mRNA cancer vaccine shows efficacy in clinical trial

mRNA cancer vaccine shows efficacy in clinical trial

Moderna and Merck announced in a mid-December 2022 press release that its mRNA cancer vaccine mRNA-4157/V940 in combination with the immune checkpoint inhibitor pembrolizumab had met its primary end ...

Horizons in vaccine production

Horizons in vaccine production

The scramble for a coronavirus vaccine over the last two years has demonstrated how important vaccines are to containing infectious disease. The coronavirus vaccine has broken the link between ...

A much-needed boost: the future of coronavirus vaccines

A much-needed boost: the future of coronavirus vaccines

Just over two years after our first blog on Covid-19, it appears that the disease is here to stay. Circulation rates are high enough that the hopes for eradication are low and, in a survey conducted ...

Digital therapeutics: the rise of digital health technologies during the Covid-19 pandemic

Digital therapeutics: the rise of digital health technologies during the Covid-19 pandemic

There is no denying that the Covid-19 pandemic has reshaped many aspects of our lives. Those lucky enough to be spared by tragedy have tried to focus on the benefits of this new way of life, like a ...

Healthy eating means more than just a balanced diet: future foods and fighting the risk of infection

Healthy eating means more than just a balanced diet: future foods and fighting the risk of infection

Human health is inextricably linked to food – not least because eating a healthy diet is known to protect against noncommunicable diseases such as cancer, diabetes, heart disease and stroke. However, ...

Read our Coronavirus blog series

Impact, Ingenuity, Innovation, Inspiration

The impact of coronavirus on IP varies depending on the technical field in which you operate and the type of IP protection that you have in place.  For many it’s business as usual at the moment, but certain sectors are being fundamentally altered by the pandemic.  For example, we’re seeing some companies initiate audits of their patent portfolios to better adapt them to a post-pandemic world.  And some brands are using the power of trade marks to emphasise government advice on social distancing, such as temporarily adapting or modifying their logos to incorporate this message.

At Mewburn Ellis we are continuing to monitor information emerging from IP offices around the world on a daily basis to ensure we are able to provide up to date practical guidance.  We are on hand to support you and your evolving IP requirements during these exceptional times.

We are inspired and humbled by the actions of our clients, colleagues and friends who are playing a crucial role in the fight against Coronavirus (COVID-19).  We’re mentioning just a few here, but hope to recognise more over time.

Thank you to:

  • A*STAR who have successfully developed a test kit which can detect the presence of the SARS-CoV-2 virus which causes Coronavirus (COVID-19), quickly and with high accuracy. Read more.

  • AstraZeneca who as well as developing the vaccine and playing a fundamental role in the fight against the virus, have donated nine million face masks to help support healthcare workers around the world during the Coronavirus (COVID-19) pandemic. Read more.

  • BerGenBio whose AXL kinase inhibitor, bemcentinib, has been selected as a first candidate in a first wave of new and existing medicines to be tested through the Accelerating COVID-19 Research & Development: Phase 2 platform (ACCORD-2) study. Read more.

  • Biohaven Pharmaceuticals who have received FDA approval to initiate a Phase 2 study of vazegepant, an intranasal, high-affinity calcitonin gene-related peptide (CGRP) receptor antagonist, for the treatment of COVID-19 infection associated pulmonary complications.  Read More.

  • Biotest AG who are participating in cross-industry schemes to develop a therapy for the treatment of COVID-19 and developing with Trimodulin a COVID-19 therapy for patients with a severe course of the disease. Read More.

  • Bristol Myers Squibb who have responded to the COVID-19 crisis with initiatives including the expansion of their patient support programs and by donating personal protective equipment (PPE) and other equipment to help those in need. Read more.

  • Cepheid who have just recieved emergency use authorisation from FDA for their Rapid SARS-CoV-2 Test. Read more.

  • Citymapper who's App is being used to collect data that can map the effectiveness of lockdown orders. Read more.

  • Flexicare who have geared up production of essential life saving devices and, in South Wales, have re-homed ventilators from its test laboratory to be used to help patients who need them the most. Read more.

  • Illumina who is paving the way for large-scale, next-generation sequencing-based (NGS) COVID-19 testing. Read more.

  • Innate Pharma who have announced the start of a double-blind Phase II clinical trial, evaluating the safety and efficacy of its anti-C5aR antibody, avdoralimab (IPH5401), in COVID-19 patients with severe pneumonia. Read More.

  • Kings College London who have committed £500k in funding for new and immediate Coronavirus research. Read more.

  • MiRXES who have produced a diagnostic test kit for Coronavirus (COVID-19). Read more.

  • PacBio who is supporting academic and commercial labs in their efforts to understand SARS-CoV-2 and Coronavirus (COVID-19). Read more.

  • Shinogi & Co., Ltd who is developing an antibody-test kit for Coronavirus (COVID-19). Read more.

  • Unilever who will contribute €100m to help the fight against the pandemic through donations of soap, sanitiser, bleach and food. Read more.

  • Wellcome who have joined the UK government, industry and universities in a step-change to COVID-19 testing.  Read more.

If you or your company are in a position to support the Coronavirus effort, the UK Government have set up a scheme to enable businesses to get involved.  Find out more on the Offer Coronavirus (COVID-19) support from your business webpage.

covid-19 trademark

Staying Covid Secure

Our offices comply with the government's guidance on managing the risk of COVID-19

Our offices are now open and our people are returning on a phased basis with the aim of everyone being back in at least some of the time from the end of September. To keep our people as safe as possible, we have taken the decision to maintain our offices as COVID-19 secure and the screens, one way systems, mask use and social distancing remain in place. We believe this is a sensible approach for now to maintain the health and wellbeing of our staff.

COVID CERTIFICATE

Coronavirus (COVID-19) - Useful Links

COVID-19: support for businesses

The UK Government has set up temporary measures to support businesses through this period of disruption caused by COVID-19.  Read more at GOV.UK

COVID-19: guidance for employees, employers and businesses

The UK Government has provided guidance for employees, employers and businesses.  Read more at GOV.UK

The Coronavirus Business Interruption Loan Scheme (CBILS)

The Coronavirus Business Interruption Loan Scheme (CBILS) provides financial support to smaller businesses (SMEs) across the UK that are losing revenue, and seeing their cashflow disrupted, as a result of the COVID-19 outbreak.  The scheme is a part of a wider package of government support for UK businesses and employees. Read more at the UK Government’s Business Support website.

Covid Corporate Financing Facility (CCFF)

Financial support for larger firms by way of the Bank of England’s Covid Corporate Financing Facility is open for applications.

EPO Coronavirus (COVID-19) Updates

The European Patent Office (EPO) now has a dedicated webpage regarding their response to COVID-19  that provides current information as the crisis unfolds.

UKIPO Coronavirus (COVID-19) Updates

The UKIPO has provided a Coronavirus update on IPO services.

EUIPO COVID-19 Information

The EUIPO has a page which provides regular updates.

WIPO's COVID-19 Response

WIPO has launched various iniatiaves to deal with the disruption caused by COVID-19.

Coronavirus and your wellbeing

Mind have put together some guidance on things you can try that could help your wellbeing.

If you need advice on how Coronavirus could affect your approach to IP - talk to our Coronavirus (COVID-19) experts

MEET THE TEAM
Forward Magazines Overlapping 8

Mewburn Ellis

FORWARD MAGAZINE

Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.